Right to Try Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (May 4, 2017)
Right to Try Act
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.
What just happenedJun 7, 2017
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Who’s behind it
- Introduced in HouseMay 4, 2017
- Jun 7, 2017Committee
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Crime and Federal Government Surveillance Subcommittee - Jun 7, 2017Committee
Referred to the Subcommittee on the Constitution and Civil Justice.
Constitution and Limited Government Subcommittee - May 5, 2017Committee
Referred to the Subcommittee on Health.
Health Subcommittee - May 4, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Judiciary Committee - May 4, 2017IntroReferralH11100-A
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- May 4, 2017IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - May 4, 2017IntroReferralIntro-H
Introduced in House
- May 4, 2017IntroReferral1000
Introduced in House